hVIVO (LON:HVO) Shares Down 46.3% – Time to Sell?

Shares of hVIVO plc (LON:HVO) were down 46.3% during mid-day trading on Saturday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares traded hands during mid-day trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analysts Set New Price Targets

Separately, Shore Capital reiterated a “buy” rating on shares of hVIVO in a research note on Friday.

hVIVO Stock Down 46.3%

The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm’s 50 day simple moving average is GBX 16.16 and its 200-day simple moving average is GBX 18.04. The stock has a market capitalization of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO) last released its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Equities analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insider Activity at hVIVO

In other hVIVO news, insider Yamin Mo’ Khan sold 3,062,246 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). 14.03% of the stock is owned by company insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.